The last few years have seen considerable evolution in treatment options and therapeutic strategies for patients with castrateresistant prostate cancer (CRPC). One major change was the expansion of chemotherapeutic options with the approval of cabazitaxel, representing the first chemotherapeutic therapy after docetaxel to demonstrate improved survival in patients with CRPC. A number of other noncytotoxic therapies have either recently been approved or are in advanced development for treating this patient population. Offering novel mechanisms of action, these new agents make considerably more expansive and complex the decisions regarding when to treat, which agents to use, and the order in which they are administered. A pivotal decision point for urologists who treat patients with advanced prostate cancer has been timing the patient's referral to an oncologist for chemotherapy. Although clinical guidelines regard chemotherapy as only appropriate for prostate cancer patients with symptomatic metastatic disease, increasing evidence points to the possibility that a subgroup of patients may benefit from an earlier introduction of chemotherapy. At the same time, additional treatment options that may either precede chemotherapy or follow initial chemotherapeutic failure mean that urologists must closely monitor their patients' health status to match specific clinical profiles with specific treatment options. With the increase in number and variety of therapeutic approaches, the role of the urologist has been expanded, in part, owing to the opportunity for urologists to administer treatments previously unavailable, and also owing to the growing importance of working cooperatively with oncologists and as a member of a multidisciplinary team.
NEW TREATMENTS, NEW ROLES, NEW DECISIONS
It has long been assumed that the progression of prostate cancer (PC) refractory to hormone therapy occurs in a relatively fixed manner, independent of androgen and androgen receptor interaction. This conventional wisdom, however, has been overturned over the past several years with findings that demonstrate both variability in refractory patterns of advanced disease to secondary hormone treatment, as well as an unexpected dependence (which is to say, lack of independence), in many cases, of disease progression upon the interaction between androgen and androgen receptors. 1 As our understanding of PC expands, commensurate development in new therapies and therapeutic strategies also evolves. The role of chemotherapy in PC is no exception, as new chemotherapeutic agents and novel paradigms for their application have emerged in recent years.
Before the demonstration of survival benefit with docetaxelbased chemotherapy in 2004, the role of chemotherapy was primarily palliative in nature. 2, 3 Palliative care has traditionally been the province of oncologists who have also been responsible for providing chemotherapy for patients with advanced PC. 4 As the providers of palliative care, oncologists are well aware of the degree of pain experienced by patients. This awareness in patients with PC has thus inclined oncologists to initiate chemotherapy as early as possible, partly not only in order to alleviate pain but also to time treatment initiation at the lowest possible level of baseline pain, recognizing that higher levels of baseline pain are associated with poorer outcomes with chemotherapy. 5, 6 Thus, before 2004, when a patient's disease had progressed despite having undergone medical or surgical castration, the patient was typically referred by a urologist to an oncologist for palliative treatment. However, since 2004, such patients have been referred to oncologists for chemotherapy for the extended survival it may confer. 3 In 2010, an additional chemotherapeutic option emerged with the demonstration of a survival benefit with cabazitaxel in patients with metastatic, castrate-resistant PC (mCRPC) who failed docetaxel therapy. 7 The success in extending survival in mCRPC patients with cabazitaxel resulted in a secondline chemotherapy and extended the potential viability of a chemotherapy-based approach to treating patients with mCRPC.
Along with cabazitaxel, a variety of new therapies are in the process of expanding the CRPC armamentarium; together, these new therapies are challenging the traditional paradigm of treatment in advanced PC. As will be discussed below, several agents in this new wave of treatment options offer alternative mechanisms of action that are intended to treat PC in novel ways when compared with taxane-based therapies. As a consequence, the role of the urologist in treating advanced PC has become both more involved and complicated, considering that the urologist has not only additional treatment options, but new therapeutic strategies from which to choose and apply.
The decision regarding when to refer a patient with advanced PC to an oncologist, a fundamental step in the treatment of the largest proportion of CRPC patients, must now address a more complicated set of decisions. Specifically, which of the growing number of options are optimal for a given patient? In what order should the selected therapies be given? By which practitioner should the selected treatments be undertaken? Is a coordinated or multidisciplinary approach the best choice for a specific patient?
The growing importance of multidisciplinary teams in the treatment of advanced PC, including urologists, oncologists, and other relevant professionals, means that in many cases, the decision-making and formulation of a treatment strategy will be shared with other members of the team. 8 Ultimately, the availability of more therapeutic options combined with the expertise of multidisciplinary teams will likely allow for an enhanced extension of survival in a greater number of patients. The present article examines new and emerging treatments for advanced PC and discusses the role and considerations of the urologist in the context of these new options.
CONSIDERATIONS FOR UROLOGISTS IN THE SELECTION OF THERAPY
Although the terms 'castrate resistant' and 'hormone refractory' are often used interchangeably in PC, in fact, patients who are castrate resistant may possess residual sensitivity to secondary hormoneassociated therapies, whereas the patient who is truly hormone refractory will not.
9 Table 1 shows the European Association of Urology (EAU) guidelines' definition of CRPC. 9 For patients with CRPC who have failed hormone therapy, both the National Comprehensive Cancer Network (NCCN) and EAU treatment guidelines advocate the use of secondary hormone therapy in patients with little or no evidence of metastases, despite the fact that no survival benefit has been demonstrated with these therapies. 9, 10 The EAU guidelines' rationale for this approach is that secondary hormone therapy has the potential for delaying the initiation of chemotherapy in these patients as well as slowing the rate of increase in PSA levels. Although no secondary hormone therapy has shown a prolongation of survival, PSA decreases of 450% have been reported in a large proportion of patients, with an effective therapeutic duration between 2 and 6 months.
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Both guidelines also advocate chemotherapy exclusively in CRPC patients with metastases, unless they are participating in a clinical trial. 9, 10 The EAU guidelines further suggest that CRPC patients be managed by a multidisciplinary team. 9 The urologist managing a PC patient who has failed initial hormone therapy must then determine if the patient is a candidate for secondary hormone therapy, chemotherapy, or some other or additional therapeutic intervention. In the case of patients with symptomatic mCRPC, the path of referral for chemotherapy remains the standard approach for patients who accept it and for whom there is no contraindication. There exists, for many patients, an interim period after the failure of initial hormone therapy (or after secondary hormone therapy failure if it has been undertaken) when the choice of optimal treatment can be difficult to determine. The urologist may choose to continue overseeing the patient's therapy at this point, or may choose to refer the patient to an oncologist. The role of a multidisciplinary team to establish a treatment strategy at this stage becomes particularly important because a referral to an oncologist should ideally be done in the context of a treatment plan rather than owing to a lack of other options ( Figure 1) . 12 Should the patient be referred to an oncologist with no strategy in place, the oncologist may determine that he/she has no appropriate treatment available at that stage, and either send the patient back to the urologist or simply ask him to wait. In either scenario, the patient is likely to be discouraged and may lose confidence in his physicians.
If chemotherapy is to be initiated, the timing of treatment often remains a less-than-obvious choice despite the direction of the treatment guidelines. If a patient is referred too late, the chances of successful treatment are reduced; too early, and patient 'limbo' may occur in which the oncologist determines that he/she has no immediate treatment options for the patient. It is also the case that the choice to initiate chemotherapy may not require a referral as a number of urology practices have taken on the responsibility of administering chemotherapy themselves. 13 
TIMING OF THE INITIATION OF CHEMOTHERAPY
Although the NCCN guidelines require that chemotherapy only be given to patients with symptomatic metastatic disease, guidance for managing the asymptomatic patient is less certain. 10 The EAU guidelines state that patients with asymptomatic mCRPC who have elevated PSA levels or PSA doubling time o6 months should be started on cytotoxic therapy early in order to increase the opportunity for extended survival. 9 A potential tension between urologist and oncologist may occur when such clear evidence for early chemotherapy is not present. It is frequently the case that the oncologist regards the first sign of symptomatic disease as a compelling indication for the initiation of chemotherapy in order to maximize treatment efficacy. The urologist may, however, be inclined to delay therapy until absolutely necessary in order to spare the patient the adverse effects (AEs) of chemotherapy.
In the TAX 327 trial, which initially demonstrated survival benefit with docetaxel therapy, those patients without baseline Castrate serum levels of testosterone (testosterone o50 ng dl À1 or o1.7 nmol l À1 ) Three consecutive rises of PSA, 1 wk apart, resulting in two 50% increases over the nadir Antiandrogen withdrawal for at least 4 wk for flutamide and for at least 6 wk for bicalutamide PSA progression, despite consecutive hormonal manipulations Progression of osseous lesions: progression or appearance of two or more lesions on bone scan or soft tissue lesions using Response Evaluation Criteria in Solid Tumors and with nodes 42 cm in diameter Abbreviations: EAU, European Association of Urology. Reprinted from Ref. 9 , with permission from the European Association of Urology. pain were able to receive chemotherapy for a significantly greater duration compared with those with baseline pain (median 27 vs 21 weeks; P ¼ 0.0017). 5 Moreover, those without baseline pain experienced significantly greater overall survival (OS) than those with pain (hazard ratio (HR) 0.73 vs 0.85; 95% confidence interval (CI), 0.57--0.93; P ¼ 0.01). 5, 6 Taken together, these data point to the potential benefits of earlier chemotherapy, although such a decision depends upon the profile of each particular patient. Chemotherapy for nonmetastatic patients is discouraged by treatment guidelines except within clinical trials; however, some limited trial data suggest a benefit to a subgroup of these patients with chemotherapy. 14, 15 A prognostic nomogram developed by Armstrong et al. 15 and based on results from TAX 327 demonstrated that patients with lower PSA (o114 ng ml À1 ) and slower PSA doubling time (X55 days) had significantly greater survival than patients with higher PSA or faster PSA doubling time. The analysis of clinical trial data by Hussain et al.
14 also revealed that PSA progression, defined as an increase in PSA of at least 25% over nadir, or an absolute increase of 2 ng ml À1 (based on the Prostate Cancer Working Group 2008 definition) or 5 ng ml À1 (based on the Prostate Cancer Working Group 1999 definition), was predictive of OS in both patients with CRPC on chemotherapy and newly diagnosed patients with hormone-sensitive PC treated with continuous androgen deprivation therapy. Based on these data, the predictive validity of PSA kinetics regarding response to chemotherapy and the threshold for initiation of chemotherapy in asymptomatic patients may, in some cases, be appropriate if their PSA-related values support it. 16 The availability of other therapeutic options at this interim period, such as immunotherapy or other options (discussed below), may be seen as preferable at this stage by some urologists and medical oncologists. Still, the data discussed above may incline a urologist to direct patients to consult with an oncologist as soon as localized therapy is no longer adequate.
NEW FOOD AND DRUG ADMINISTRATION (FDA)-APPROVED THERAPIES IN ADVANCED CANCER TREATMENT
Abiraterone acetate Abiraterone is a synthetic pregnenolone derivative with selective and irreversible inhibition of CYP17. 17 Administered orally, abiraterone was recently approved by both the US FDA and the European Medicines Agency in combination with prednisone for the treatment of patients with mCRPC who have failed docetaxel therapy. The pivotal phase III trial of abiraterone was a multicenter study conducted in 13 countries and involving 1195 mCRPC patients randomized to receive 5 mg prednisone twice a day with either placebo (n ¼ 398) or abiraterone 1000 mg (n ¼ 797). 18 The primary endpoint was overall OS, and after a median follow up of 12.8 months, OS was 14.8 months for those treated with abiraterone---significantly longer (Po0.001) than the 10.9 months OS seen in the placebo group (HR 0.65; 95% CI, 0.54--0.77; Figure 2 ). 18 Secondary endpoints also favored abiraterone over placebo. Time to PSA progression (defined as per the Prostate Cancer Working Group 1999) was 10.2 months for patients treated with abiraterone vs 6.6 months for patients administered placebo (Po0.001).
18 Progression-free survival was 5.6 months in the abiraterone group compared with 3.6 months in the placebo group (Po0.001), and the PSA response rate also favored the abiraterone-treated patients (29 vs 6%; Po0.001). AEs associated with CYP17 blockade were significantly more common in the abiraterone group; in particular, edema (31 vs 22%; P ¼ 0.04) and hypokalemia (17 vs 8%; Po0.001).
18
The most recent update to the NCCN treatment guidelines note that abiraterone is one of several options among treatments for CRPC patients with symptomatic and/or visceral disease for whom chemotherapy is contraindicated, and also is one of several second-line options for patients who have failed docetaxel therapy. 10 In March 2012, a phase III trial of abiraterone in patients with asymptomatic or mildly symptomatic CRPC who were also chemotherapy naive was unblinded and, at the recommendation of the Independent Data Monitoring Committee, abiraterone treatment was offered to the patients on placebo. This action was taken subsequent to a planned interim analysis that revealed clinical benefit with abiraterone treatment based on achievement of primary and secondary endpoints in the trial. 19 As abiraterone is an oral agent, it can be prescribed by any physician, but is ultimately self-administered by the patient. This fact somewhat alters the conventional physician/patient relationship in which most major CRPC therapies require direct interaction between the patient and urologist and/or oncologist. It may also alter the relationship between the urologist and oncologist, considering that the urologist can prescribe abiraterone, independent of oncologist involvement. Furthermore, although patientspecific treatment has always been an important factor in the selection of treatment in CRPC, the emergence of abiraterone and other treatments with novel mechanisms of action allows for greater discussion among a multidisciplinary team. Cabazitaxel Cabazitaxel, a novel taxane agent, was approved by the FDA in 2010 as a second-line agent in combination with low-dose prednisone for the treatment of patients with mCRPC who have already undergone docetaxel-based therapy. Cabazitaxel is the only chemotherapeutic agent to have demonstrated survival in a second-line mCRPC setting. 7 Pivotal in the approval of cabazitaxel was data from the TROPIC trial, a multicenter study conducted in 26 countries which compared cabazitaxel with mitoxantrone in 755 men with mCRPC who had previously failed docetaxel therapy. 7 Patients received 10 mg daily prednisone in addition to either 25 mg m À2 intravenous cabazitaxel (n ¼ 378) or 12 mg m À2 intravenous mitoxantrone (n ¼ 377) on day 1 of consecutive 21-day treatment cycles with a maximum of 10 treatment cycles. 7 OS was the primary endpoint in the TROPIC trial, and after a median follow up of 12.8 months, OS for patients treated with cabazitaxel was 15.1 months compared with 12.7 months for the mitoxantrone-treated patients, a 30% relative risk reduction (HR 0.70; 95% CI, 0.59--0.83; Po0.0001; Figure 3 ). Treatment efficacy with cabazitaxel was Figure 2 . Kaplan--Meier overall survival estimates for patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate or placebo (both plus prednisone). 18 consistent across patient subgroups classified by baseline prognostic factors. 7 Secondary endpoints also favored cabazitaxel. Progression-free survival was of longer duration for patients administered cabazitaxel vs mitoxantrone (2.8 vs 1.4 months, respectively; HR 0.74; 95% CI, 0.64--0.86; Po0.0001). Tumor response, PSA response, time to tumor progression, and time to PSA progression were also significantly superior with cabazitaxel compared with mitoxantrone. With regards to AEs, 8% of the cabazitaxel group experienced grade 3/4 febrile neutropenia, suggesting that treatment with granulocyte-colony stimulating factor may be necessary in patients aged 465 years and others at high risk for febrile neutropenia. 7 The NCCN guidelines recommend cabazitaxel for patients who have failed docetaxel therapy and are not high risk vis-à-vis neutropenia. 10 A randomized, open-label, head-to-head trial of cabazitaxel vs docetaxel in mCRPC is currently underway (ClinicalTrials.gov ID #NCT01308567). Should sufficient clinical data become available to demonstrate superiority to docetaxel in this patient population, it is conceivable that it could become a first-line therapy.
Denosumab
Denosumab is a RANK (receptor activator of NF-kB) ligand inhibitor that was approved in 2010 for the prevention of skeletal-related events for patients with bone metastases from solid tumors. The NCCN guidelines recommend denosumab or zoledronic acid in patients with metastases in order to prevent skeletal-related events, with a preference for the former due to its demonstrated superior efficacy. 10 The utility of denosumab in CRPC is likely to expand in light of recently reported results presented at the 2011 American Urological Association annual meeting, which demonstrated that denosumab significantly improved bone metastasis-free survival by 4.2 months vs placebo (29.5 vs 25.2 months, HR 0.85; P ¼ 0.028). 20 This constituted a 15% risk reduction. OS was not improved with denosumab treatment, but a 33% reduction in symptomatic metastases vs placebo (P ¼ 0.01) was observed in the study.
In order to increase bone mass, denosumab is also indicated for use in men with nonmetastatic PC who are receiving androgendeprivation therapy and are at an elevated risk for fracture. 21 An application for an additional denosumab indication for the prevention of bone metastases in CRPC was submitted, but due to the potential risks associated with denosumab treatment, including the risk of osteonecrosis of the jaw, it was rejected in its current form by the FDA in early 2012. 22 A revised application for approval may be forthcoming and would constitute another meaningful change in the CRPC treatment landscape. The availability of a treatment that would delay the development of bone metastases would also likely delay the initiation of chemotherapy for many patients. Although it is not known what the role of denosumab in therapy would be should it receive this additional indication, it is likely that it would be used as a parallel treatment with other antitumor therapies, rather than as a substitute. Denosumab, which is administered subcutaneously, might also provide urologists with an additional treatment that could be administered without the collaboration of oncologists.
Sipuleucel-T Sipuleucel-T is a vaccine-based immunotherapy in which autologous antigen-presenting cells are obtained from the patient, activated through co-culturing with prostatic acid phosphatase, and infused into the patient in order to stimulate a T-cell immune response. 23 Sipuleucel-T is indicated for the treatment of men with asymptomatic or minimally symptomatic mCRPC. 24 The efficacy of sipuleucel-T was assessed in three phase III trials in asymptomatic CRPC patients. The first trial demonstrated that patients receiving sipuleucel-T experienced a median 4.5-month survival benefit compared with placebo during the 3-year study (P ¼ 0.01). 25 In the second phase III trial, a 20% survival benefit 43 years was observed with sipuleucel-T treatment. 23 The third phase III trial, the IMPACT study, involved 512 patients randomized 2:1 to receive sipuleucel-T or placebo, respectively. 26 After a median follow up of 34.1 months, patients receiving sipuleucel-T experienced a 4.1-month survival benefit (25.8 vs 21.7 months) 43 years---a 22% risk reduction (P ¼ 0.03; Figure 4 ). 26 Sipuleucel-T is the first and only therapeutic vaccine to demonstrate OS benefit, and received FDA approval in April 2010. The availability of sipuleucel-T means that another treatment that could precede chemotherapy may be used by either urologists or oncologists, although only in a subset of patients with less-advanced disease. The NCCN treatment guidelines state that the use of sipuleucel-T may be considered in patients with mCRPC who have an estimated life expectancy 46 months, no visceral disease, limited or no symptoms, and an Eastern Cooperative Oncology Group performance status of 0--1. 10 Limiting the indication of sipuleucel-T to minimally symptomatic or asymptomatic patients means that ensuring the correct timing of its use will require close monitoring of disease progression so that patients may receive treatment as soon as its use is deemed appropriate. It also avoids delays in treatment so that clinical advancement of symptoms and tumor burden do not arise and exclude its use.
OTHER EMERGING AGENTS MDV3100 MDV3100 is an orally administered androgen receptor antagonist that prevents nuclear translocation and its DNA binding. 27 A phase I/II study by Scher et al. 28 published in 2010 included 140 patients with mCRPC, some of whom were chemotherapy naive, whereas others had previous chemotherapy exposure. Patients received five different doses of MDV3100, ranging from 30 to 480 mg daily. Antitumor activity was observed for all doses, whether the patients had previously received chemotherapy or not. 28 In November 2011, the phase III AFFIRM trial of MDV3100 in 1199 men with advanced PC who had previously failed docetaxel therapy was halted after interim results demonstrated a 4.8-month survival advantage with MDV3100 treatment compared with placebo (18.4 vs 13.6 months). 29 Final data from the AFFIRM trial were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in 2012. The FDA is currently reviewing an application for MDV3100 in the treatment of CRPC.
Radium-223
Radium-223 is a bone-seeking radionuclide that, in a phase II trial, demonstrated a significant reduction in bone-alkaline phosphatase concentration in CRPC patients with bone metastases compared with placebo (Po0.0001). 30 Radium-223 also significantly extended OS (P ¼ 0.020) and significantly reduced time to PSA progression (P ¼ 0.048). 30 Results from the phase III ALSYMPCA trial were initially presented at the European Multidisciplinary Cancer Congress in September 2011. ALSYMPCA included 922 symptomatic patients with CRPC, at least two bone metastases, and no visceral disease; 58% had previously received docetaxel. 31 Subjects were randomized to receive standard-of-care therapy plus either radium-223 (n ¼ 615) or placebo (n ¼ 307) in the form of six injections every 4 weeks. The primary endpoint, OS, significantly favored radium-223 patients (14.0 vs 11.2 months; HR 0.70; 95% CI, 0.55--0.88; P ¼ 0.002). These survival data caused the study to be halted in order that placebo patients could be offered radium-223 therapy. Limited information regarding AEs was provided, except that grade 3/4 neutropenia was observed in 1.8% of radium-223 patients and 0.8% of placebo patients. Although the role in therapy for radium-223 would appear to be for patients with later-stage CRPC, it remains unclear at present whether it might be used before, during, and/or after chemotherapy in patients with mCRPC.
Two other orally administered agents currently in development for the treatment of CRPC are of particular interest. XL-184 (cabozantinib) is an inhibitor of MNNG HOS transforming gene and vascular endothelial growth factor receptor 2, both of which are involved in tumor angiogenesis and implicated in bone metastases formation. 32 XL-184 was studied in a phase II trial in patients with progressive CRPC, and demonstrated positive effects on bone metastases, markers of osteoblast and osteoclast activity, and bone pain. This resulted in an unblinding of the study in order that patients on placebo could receive XL-184.
Tasquinimod is a quinoline-3-carboxamide derivative that inhibits tumor angiogenesis. In phase I studies, it demonstrated safety and a positive effect on PSA progression and bone lesions in patients with CRPC, 33 and in a recently published phase II study, 34 was evaluated in 201 men with mCRPC. The primary endpoint for the latter study was proportion of patients without disease progression at 6 months. 34 Of the patients receiving tasquinimod, 69% were progression free at 6 months compared with 37% of placebo patients (Po0.001); the median duration of progression-free survival was 7.6 months in the tasquinimod group compared with 3.3 months in the placebo group (P ¼ 0.004). 34 Grade 3 or 4 AEs occurred in 40% of patients vs 10% of those receiving placebo; these AEs primarily consisted of asymptomatic laboratory parameter changes. Eighteen (9%) incidences of deep vein thrombosis occurred in the tasquinimod group, nine of which were classified grade 3/4 compared with none in the placebo group. 34 
CONCLUSIONS
The role of the urologist is undergoing changes in parallel with the expanding treatment options for CRPC patients. The historic treatment paradigm for patients with CRPC has been the initiation of hormone therapy with the option for secondary hormone therapy, followed by a referral to an oncologist for chemotherapy. The availability of new agents such as abiraterone and sipuleucel-T, as well as oral agents in phase III trials and noncytotoxic infusion therapies, each with different mechanisms of action and highly particular indications, demonstrates the potential for a more complex treatment paradigm, and enables more patient-specific treatment strategies. At the same time, the approval of cabazitaxel for second-line cytotoxic therapy expands the options for a chemotherapeutic approach to treatment.
The emerging treatment landscape is one in which urologists' options are expanding dramatically, requiring that they be knowledgeable about the growing treatment armamentarium, while also requiring the close monitoring of patients in order to determine which treatments are optimal based on a given patient's current disease and health status. Coordinated care approaches between various specialties must also be emphasized and encouraged, particularly considering the increased complexity of treatment strategies and the need to bring to bear a crosssection of specialist expertise. At the same time that noncytotoxic therapies are creating new treatment options both separate and in addition to chemotherapy, newer data also point to the potential efficacy of chemotherapy in a patient population beyond the metastatic (and often symptomatic) patients who are, at present, considered therapeutic candidates. The way of the future in CRPC treatment points to the application of multiple agents, each with a particular efficacy at a particular stage of disease, administered to the same patient at various times with appropriate sequencing.
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